NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Radiotherapy|Immunotherapy|Microsatellite Instability-High Solid Malignant Tumour|Metastasis From Malignant Tumor of Liver|Squamous Cell Carcinoma of Head and Neck|Metastasis From Malignant Tumor of Cervix|Metastatic Renal Cell Carcinoma|Metastasis From Malignant Melanoma of Skin (Disorder)|Metastatic Triple-Negative Breast Carcinoma|Metastatic NSCLC|Metastasis From Malignant Tumor of Bladder (Disorder)
Interventions: DRUG: NBTXR3|RADIATION: SABR|DRUG: Nivolumab|DRUG: Pembrolizumab
Sponsor: Nanobiotix